Lindbrook Capital LLC Has $75,000 Holdings in Karuna Therapeutics, Inc. (NASDAQ:KRTX)

Lindbrook Capital LLC grew its position in Karuna Therapeutics, Inc. (NASDAQ:KRTX) by 105.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 238 shares of the company’s stock after acquiring an additional 122 shares during the quarter. Lindbrook Capital LLC’s holdings in Karuna Therapeutics were worth $75,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Signaturefd LLC increased its position in Karuna Therapeutics by 266.7% in the 3rd quarter. Signaturefd LLC now owns 275 shares of the company’s stock worth $46,000 after purchasing an additional 200 shares during the last quarter. Exchange Traded Concepts LLC increased its position in Karuna Therapeutics by 34.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 452 shares of the company’s stock worth $76,000 after purchasing an additional 116 shares during the last quarter. JGP Global Gestao de Recursos Ltda. bought a new stake in shares of Karuna Therapeutics during the 4th quarter worth about $222,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Karuna Therapeutics by 98.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 971 shares of the company’s stock worth $164,000 after acquiring an additional 481 shares in the last quarter. Finally, Knights of Columbus Asset Advisors LLC boosted its stake in shares of Karuna Therapeutics by 5.7% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 1,152 shares of the company’s stock worth $195,000 after acquiring an additional 62 shares in the last quarter.

Insider Transactions at Karuna Therapeutics

In other news, insider Stephen K. Brannan sold 5,000 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $316.13, for a total value of $1,580,650.00. Following the completion of the transaction, the insider now directly owns 41,150 shares of the company’s stock, valued at approximately $13,008,749.50. The sale was disclosed in a legal filing with the SEC, which is available at this link. 13.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have recently issued reports on KRTX shares. HC Wainwright reiterated a “neutral” rating and set a $330.00 price target on shares of Karuna Therapeutics in a research note on Thursday, March 14th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $330.00 price target (up previously from $217.00) on shares of Karuna Therapeutics in a research note on Thursday, December 28th. Mizuho reiterated a “neutral” rating and set a $330.00 price target (up previously from $245.00) on shares of Karuna Therapeutics in a research note on Friday, January 26th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $330.00 price target on shares of Karuna Therapeutics in a research note on Tuesday, February 20th. Ten analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Karuna Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $293.92.

Karuna Therapeutics Stock Performance

Shares of KRTX stock opened at $329.83 on Thursday. The stock has a 50 day moving average of $325.22 and a two-hundred day moving average of $269.92. Karuna Therapeutics, Inc. has a 12 month low of $158.38 and a 12 month high of $329.99. The company has a market capitalization of $12.58 billion, a P/E ratio of -28.14 and a beta of 1.18.

Karuna Therapeutics (NASDAQ:KRTX) last issued its earnings results on Thursday, February 22nd. The company reported ($3.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.65) by ($0.36). During the same period last year, the business earned ($2.22) earnings per share. The firm’s revenue was down 100.0% on a year-over-year basis. Sell-side analysts predict that Karuna Therapeutics, Inc. will post -11.96 earnings per share for the current fiscal year.

Karuna Therapeutics Company Profile

Karuna Therapeutics, Inc, a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease.